Argos Therapeutics Inc.: Argos Therapeutics to Hold Second Quarter 2015 Financial Results Conference Call on Wednesday, August 12, 2015

Tickers: ARGS
DURHAM, N.C., Aug. 5, 2015 (GLOBE NEWSWIRE) -- Argos Therapeutics, Inc. (NASDAQ:ARGS), an immuno-oncology company focused on the development and commercialization of fully individualized immunotherapies for the treatment of cancer based on the ArcelisĀ® technology platform, today announced that the Company's second quarter 2015 financial results will be released after market close on Wednesday, August 12, 2015. Argos executive management will host a conference call beginning at 4:30 p.m. Eastern Time to discuss these results and to answer questions.

To participate by telephone, please dial (855) 433-0930 (Domestic) or (484) 756-4271 (International). The conference ID number is 3804616. A live and archived audio webcast can be accessed through the Investors section of the Company's website at www.argostherapeutics.com. The archived webcast will remain available on the Company's website for fourteen (14) days following the call.

Top Company Interviews

Microsoft Corporation
Intel Corporation
Pfizer, Inc.
General Electric Company
About Argos Therapeutics

Argos Therapeutics is an immuno-oncology company focused on the development and commercialization of fully individualized immunotherapies for the treatment of cancer using its ArcelisĀ® technology platform. Argos' most advanced product candidate, AGS-003, is being evaluated in the pivotal ADAPT phase 3 clinical trial for the treatment of metastatic renal cell carcinoma (mRCC). The Company is also developing a separate ArcelisĀ®-based product candidate, AGS-004, for the treatment of HIV, currently being evaluated in a phase 2 clinical trial aimed at HIV eradication in adult patients. For more information about Argos Therapeutics, visit www.argostherapeutics.com.

CONTACT: Media:

         Adam Daley

         Berry & Company Public Relations

         adaley@berrypr.com

         (212) 253-8881



         Investors:

         John MendittoArgos Therapeutics, Inc.jmenditto@argostherapeutics.com

         919-908-0687
Source: Argos Therapeutics, Inc.

News Provided by Acquire Media

distributed by

This content was issued by Argos Therapeutics Inc. on the 2015-08-05 and was initially posted on www.argostherapeutics.com. It was distributed, unedited and unaltered, by noodls on 2015-08-05 12:59:11 UTC. The original issuer is solely responsible for the accuracy of the information contained therein.